Underactive Bladder Market Share, Size, Trends, Industry Analysis Report, By Treatment Type (Pharmacotherapy, Surgical Methods, Urethral Assist Device, Stem Cell and Gene Therapies); By Route of Administration; By End User; By Distribution Channel; By Reg

Underactive Bladder Market Share, Size, Trends, Industry Analysis Report, By Treatment Type (Pharmacotherapy, Surgical Methods, Urethral Assist Device, Stem Cell and Gene Therapies); By Route of Administration; By End User; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032

The global underactive bladder market size is expected to reach USD 728.06 Million by 2032, according to a new study by Polaris Market Research. The report “Underactive Bladder Market Share, Size, Trends, Industry Analysis Report, By Type (Pharmacotherapy, Surgical Methods, Urethral Assist Device, Stem Cell and Gene Therapies); By Route of Administration; By End User; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The prevalence of underactive bladder is expected to rise in the future due to various factors, including the increasing aging population. As people age, their bladder muscles weaken, resulting in a reduction in bladder function and an elevated risk of underactive bladder. The underactive bladder market has witnessed significant growth due to advancements in medical technology that have fueled the development of new medications, surgical techniques, and non-invasive devices. These advancements have made it easier for patients to access effective treatments that can improve bladder function. In recent years, there has been considerable progress in the development of medications for underactive bladder. These medications work by increasing the contractility of the bladder muscles, which results in improved bladder function.

However, some treatments are expensive, making them unaffordable for some patients. Due to the high cost of advanced treatments such as sacral neuromodulation therapy or urethral bulking agents, some patients may avoid seeking treatment altogether.

Surgical techniques such as sacral neuromodulation have shown promise in treating underactive bladder. This technique involves implanting a device that stimulates the sacral nerve, which controls bladder function. The stimulation helps to increase bladder function, and the device can be adjusted to the individual patient's needs. Non-invasive devices such as pelvic floor muscle training devices have also emerged as viable treatment options for underactive bladder.

Underactive Bladder Market Report Highlights

In 2023, the most significant revenue share in the market for underactive bladder was held by the urethral assist device. This device was highly effective in treating urinary retention and Benign Prostatic Hyperplasia (BPH).

In 2023, the global market was dominated by hospital-based distribution channels. This is because hospitals are the primary healthcare facilities where patients with bladder disorders or urinary retention are usually diagnosed and treated.

In 2023, the market was dominated by the North American region, which encompasses the United States and Canada. This was due to various factors, such as a significant elderly population, a considerable occurrence of urinary incontinence, and a growing recognition of the ailment and its possible remedies.

The global key market players include ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC., Axonics, Inc., Boehringer Ingelheim International GmbH, Cipla Inc., Dr Reddy’s Laboratories Ltd, Novartis AG, ONO PHARMACEUTICAL CO., LTD., Orion Corporation, Pfizer Inc., Vesiflo, etc.

Polaris Market Research has segmented the underactive bladder market report based on type, route of administration, end user, distribution channel, and region:

Underactive Bladder, Type Outlook (Revenue - USD Million, 2019 - 2032)

Pharmacotherapy

Surgical Methods

Urethral Assist Device

Stem Cell and Gene Therapies

Underactive Bladder, Route of Administration Outlook (Revenue - USD Million, 2019 - 2032)

Oral

Parenteral

Others

Underactive Bladder, End User Outlook (Revenue - USD Million, 2019 - 2032)

Hospitals

Clinics

Academic and Research Institutes

Others

Underactive Bladder, Distribution Channel Outlook (Revenue - USD Million, 2019 - 2032)

Hospital Pharmacy

Retail Pharmacy

Others

Underactive Bladder, Regional Outlook (Revenue - USD Million, 2019 - 2032)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa